- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01999101
Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
September 28, 2016 updated by: Phenex Pharmaceuticals AG
A Safety Pilot Study of Px-104 in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
The primary aim of the study is to evaluate the safety and tolerability of Px-104 in NAFLD patients and to assess the influence of Px-104 on hepatic fat.
Study Overview
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Vienna, Austria, 1090
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- NAFLD patients
- Weight > 65 kg
- BMI > 25 and < 40
- Negative blood or urine pregnancy test (for females of childbearing potential) collected at screening followed by another negative serum pregnancy test collected within 24 hours prior to the first dose of study drug.
- Contraception: Female patients must be postmenopausal, surgically sterile, or if premenopausal, must be prepared to use at least two effective (≤1% failure rate) method of contraception during the course of the study and for 14 days after the end of dosing. Male patients with female partners of child bearing potential must be prepared to use at least two effective methods of contraception with all sexual partners unless they have had a prior vasectomy
- Must be willing and able to give written informed consent and agree to comply with the study protocol.
- Sinus rhythm in 12-lead ECG
Exclusion Criteria:
- Evidence of excessive alcohol, drug or substance abuse (excluding marijuana use) within 1 year of first dose.
- History or other evidence of a medical condition associated with chronic liver disease other than.
- History or other evidence of decompensated liver disease (Child-Pugh Grade B or higher), coagulopathy, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminemia, ascites, hepatic encephalopathy, and bleeding from esophageal varices are conditions consistent with decompensated liver disease.
- Concomitant intake of fibrates or statins (at least 4-6 weeks before start; considering half life of medication).
- Any clinically relevant findings in ECG (identified via 24h-Holter ECG or 12-Lead ECG) at screening
- History of any structural cardiac disease.
- In addition, patients with documented or presumed unstable coronary artery disease, stable or unstable cardiovascular disease or cerebrovascular disease.
- One or more of the following conditions: (1) poorly controlled hypertension, OR (2) screening or baseline blood pressure ≥ 160 mmHg for systolic OR (3) screening or baseline blood pressure ≥ 100 mmHg for diastolic blood pressure.
- Type I or II diabetes with HbA1C > 6.5% at screening and/or fasting plasma glucose > 7mmol/L (> 126 mg/dl).
- History or other evidence of a clinically relevant ophthalmologic disorder due to diabetes mellitus or hypertension or history or other evidence of severe retinopathy (e.g., cytomegalovirus, macular degeneration).
- Known sensibility to any ingredients contained in the investigational medicinal product (IMP)
- All conditions that do not allow magentic resonance (MR) assessments
- History of having received any investigational drug ≤ 3 months and/or 6 x half-life prior to the first dose of study drug or the expectation that such drugs will be used during the study. Patients enrolled in this study cannot be enrolled in another study for either research, diagnostic or treatment purposes.
- Woman with childbearing potential unless using adequate contraception (see inclusion criteria); females who are pregnant or breast feeding.
- History of severe allergic
- Evidence of an active or suspected cancer, or a history of malignancy within the last 2 years, with the exception of patients with basal cell carcinoma that has been excised and cured.
- History of any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study.
- History of bleeding disorders or anticoagulant use
- History or other evidence of chronic pulmonary disease associated with functional limitation.
- History of uncontrolled severe seizure disorder.
- Poorly controlled thyroid dysfunction.
- History of major organ transplantation with an existing functional graft.
- Any signs of acute infection or inflammation
- History or other evidence of severe illness, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.
- Any herbal supplements containing silymarin, tocopherol, vitamin C, riboflavins, proflavins, curcumin. (at least 4-6 months before the study)
- Positive test at screening for anti-Hepatits A virus (HAV) Immunoglobulin M (IgM), Hebatitis B surface antigen (HBsAg), Anti-Hepatits B core Antigen Immunglobulin M antibody (anti-HBc IgM Ab), or anti-HIV Ab.
- Subjects who have undergone surgery within the last 3 months.
- Subjects who have had a prior gastrointestinal surgery.
- Subjects who will be unavailable for the duration of the trial, who are unlikely to be compliant with the protocol, or who are felt to b unsuitable by the investigator for any other reason
- Imprisonment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Px-104
Px-104 capsules, 5 mg
|
28 days treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: 28 days
|
Analysis of clinical chemistry, hematology, and assessment of clinical signs and adverse events over 28 days.
Change day 28 vs. day 1
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of hepatocellular lipid content
Time Frame: day 1 and day 28
|
Measurement of hepatic fat (%) by Magnetic resonance spectroscopy (MRS), change day 28 vs. day 1
|
day 1 and day 28
|
Changes in oral glucose tolerance test (oGTT)
Time Frame: baseline and day 27
|
Measurement of plasma glucose level (mg/dL)
|
baseline and day 27
|
Change from baseline in fibroblast growth factor 19 (FGF-19)
Time Frame: days 1, 7, 14, 21 and 28
|
Measurement by ELISA (pg/mL)
|
days 1, 7, 14, 21 and 28
|
Change from baseline in plasma bile acid concentration
Time Frame: days 1, 7, 14, 21, and 28.
|
Assessment by LC-MS/MS (µmol/L)
|
days 1, 7, 14, 21, and 28.
|
Pharmacokinetics of Px-104 and conjugates
Time Frame: day 1 and day 28
|
Measurement by LC-MS/MS (ng/mL).
AUC, Cmax and other pk parameters
|
day 1 and day 28
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the Saccharose-Lactulose-Mannitol + Sucralose (SLM+S) Test to evaluate the intestinal permeability
Time Frame: baseline and day 27
|
Measurement of urinary concentrations of Saccharose, Lactulose, Mannitol and Sucralose by HPLC
|
baseline and day 27
|
Assessment of liver steatosis by CAP-Fibroscan
Time Frame: baseline and day 28
|
Measurement of hepatic fat (%) by CAP-Fibroscan
|
baseline and day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Trauner, Professor Dr med, Medical University Vienna
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2013
Primary Completion (Actual)
January 1, 2015
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
November 19, 2013
First Submitted That Met QC Criteria
November 25, 2013
First Posted (Estimate)
December 3, 2013
Study Record Updates
Last Update Posted (Estimate)
September 29, 2016
Last Update Submitted That Met QC Criteria
September 28, 2016
Last Verified
November 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PHS-Px-104-II-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Alcoholic Fatty Liver Disease
-
Naga P. ChalasaniDSM Nutritional Products, Inc.CompletedNon-Alcoholic Fatty Liver Disease | Non-Alcoholic Steatohepatitis | Non-Alcoholic Fatty LiverUnited States
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Michael Ohliger, MD PhDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingNAFLD | Non-Alcoholic Fatty Liver Disease | NASH | Non Alcoholic Fatty Liver | Non Alcoholic SteatohepatitisUnited States
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
Nehal Abou SeadaCompletedNon-Alcoholic Fatty Liver Disease
-
Better TherapeuticsArizona Liver HealthCompletedNon-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty LiverUnited States
-
Puerta de Hierro University HospitalHospital Universitario Marqués de ValdecillaNot yet recruitingNon-Alcoholic Fatty Liver Disease | Non Alcoholic SteatohepatitisSpain
-
BASF ASUnknownNASH - Nonalcoholic Steatohepatitis | Non-Alcoholic Fatty Liver Disease | Non Alcoholic Fatty LiverUnited States
-
National University Hospital, SingaporeWilmar InternationalEnrolling by invitationNAFLD | Non-Alcoholic Fatty Liver Disease | Non-Alcoholic SteatohepatitisSingapore
-
AB Biotics, SACompletedNon Alcoholic Fatty LiverMexico
Clinical Trials on Px-104
-
NCIC Clinical Trials GroupCascadian Therapeutics Inc.Completed
-
NCIC Clinical Trials GroupOncothyreon Canada Inc.Completed
-
Cascadian Therapeutics Inc.Completed
-
Cascadian Therapeutics Inc.Completed
-
Cascadian Therapeutics Inc.CompletedMetastatic Cancer | Advanced CancerUnited States
-
Cascadian Therapeutics Inc.Completed
-
Aviceda Therapeutics, Inc.TerminatedDiabetic Retinopathy | Diabetic Macular EdemaUnited States
-
ACADIA Pharmaceuticals Inc.Completed
-
Otonomy, Inc.Completed
-
Aviceda Therapeutics, Inc.RecruitingMacular Degeneration | Geographic Atrophy of the MaculaUnited States